Arranta Bio to expand manufacturing to include mRNA vaccine support

By The Science Advisory Board staff writers

September 24, 2021 -- Arranta Bio, a contract development and manufacturing organization, plans to expand its manufacturing capacity at its Watertown, MA, facility to include support for developers of mRNA vaccines.

The expanded capacity will allow the company to support infectious disease and therapeutic vaccine developers through the manufacture of raw materials, in vitro transcription, mRNA purification, and lipid nanoparticle formulation, it said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.